2. Anti-infection
  3. HPV

HPV

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) that commonly causes skin or mucous membrane growths (warts). HPV is a virus with double-stranded circular DNA from the papillomavirus family. All HPVs have icosahedral capsids. HPV displays tropism toward the epithelial basal layer, which houses adult epithelial stem cells responsible for replenishing the epithelium with daughter cells. There are more than 100 varieties of human papillomavirus (HPV). Some types of HPV infection cause warts, and some (HPV 16 and 18) can cause different types of cancer, including cancers of the anus, penis, vagina, vulva and back of the throat (oropharyngeal). Worldwide, the risk of being infected at least once in a lifetime among both men and women is 50%. Vaccines can help protect against the strains of HPV most likely to cause genital warts or cervical cancer.

HPV Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-136466
    A2ti-2 Inhibitor 99.85%
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM[1]. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection[2].
  • HY-136465
    A2ti-1 Inhibitor 99.83%
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM[1]. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection[2].
  • HY-124379
    TPCK 98.55%
    TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is a potent serine protease inhibitor that reacts with the retinoblastoma protein (RB)-binding core of HPV-18 E7 protein and abolish its RB-binding capability. TPCK is able to modify E7 protein in live keratinocytes following its addition to the culture medium[1].
  • HY-120599
    Sabizabulin Inhibitor 98.75%
    VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer[1][2][3].
  • HY-10221
    Vorinostat Inhibitor
    Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].
  • HY-P99522
    Verpasep caltespen
    Verpasep caltespen (HspE7) is a recombinant fusion protein derived from Mycobacterium bovis Calmette-Guérin heat shock protein 65 (Hsp65), the C-terminal end of which is covalently linked to the E7 protein of HPV16. Verpasep caltespen can be used in the study of precancerous and cancerous lesions caused by human papillomavirus (HPV) [1][2].
  • HY-119098
    GSK983 Inhibitor
    GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes[1].
  • HY-146033
    HPV18-IN-1 Inhibitor
    HPV18-IN-1 (Compound H1) is a potent inhibitor of HPV18. HPV18-IN-1 prevents cervical cancer cells from premature cell procession and abnormal proliferation. HPV18-IN-1 supresses E7-Rb-E2F cellular pathway and DNA methylation. HPV18-IN-1 has the potential for the research of cancer diseases[1].
  • HY-115412
    Vorinostat-d5 Inhibitor
    Vorinostat-d5 (SAHA-d5) is the deuterium labeled Vorinostat. Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].
  • HY-109045A
    Teslexivir hydrochloride Inhibitor 99.34%
    Teslexivir (BTA074) hydrochloride is a potent antiviral agent. Teslexivir hydrochloride is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an association that is a necessary step in the DNA replication and thus viral production for Human Papilloma Virus (HPV) 6 and 11. Teslexivir hydrochloride can be used for condyloma research[1].
  • HY-114698
    Retro-2 cycl Inhibitor 99.86%
    Retro-2 cycl (RN 1-001) is a dihydroquinazolinone (DHQZ) inhibitor of retrograde trafficking. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudovirus with IC50s of 54 μM and 160 μM, respectively[1]. Antiviral agent[1].
  • HY-P1778
    HPV16 E7 (86-93)
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas[1][2].
  • HY-101795
    Larixyl acetate Inhibitor
    Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction[1][2].
  • HY-P1907
    Human Papillomavirus (HPV) E7 protein (49-57)
    Human Papillomavirus (HPV) E7 protein (49-57) is the H-2d-restricted human papillomavirus (HPV) E749-57 epitope (short peptide spanning the 49th to 57th amino acid residues in the E7 protein)[1].
  • HY-P1881
    HPV16-E711-20 epitope
    HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine[1].
  • HY-109045
    Teslexivir Inhibitor
    Teslexivir (BTA074) is a potent antiviral agent. Teslexivir is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an association that is a necessary step in the DNA replication and thus viral production for Human Papilloma Virus (HPV) 6 and 11. Teslexivir can be used for condyloma research[1].
  • HY-P1778A
    HPV16 E7 (86-93) (TFA) 99.54%
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas[1][2].